UK could 'have its cake and eat it' on post-Brexit EMA membership

Health economists have given the UK an “amber warning” on the potential consequences of leaving the European Medicines Agency, in a new research paper.

Published today in the online journal of ecancer.org, the editorial was prepared by Anthony Hatswell of BresMed Health, a consultancy, and University College London.

The academics, who looked at the likely impact on UK pharmaceutical regulation and access to medicines, argue that withdrawal from the EMA will likely delay the availability of new medicines to the UK market.